Hodgkin's lymphoma in adults

The Lancet

Volumn 380, Issue 9844, 2012, Pages 836-847

  Townsend, William ^a   Linch, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; LENALIDOMIDE; PANOBINOSTAT; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; ELDERLY CARE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865581183     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60035-X     Document Type: Review

References (133)

1. Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003; 361: 943-51. (Pubitemid 36332113)
2. National Cancer Institute. SEER stat fact sheets: Hodgkin lymphoma. http://seer.cancer.gov/statfacts/html/hodg.html (accessed Aug 31, 2011).
3. Cancer Research UK. Cancer stats incidence 2008\UK. 2011 http://info.cancerresearchuk.org/prod-consump/groups/cr-common/@nre/@sta/ documents/generalcontent/cr-072111.pdf (accessed Aug 31, 2011).
4. Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol 2011; 2011: 725219.
5. Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol 2010; 20: 30-44.
6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-76. (Pubitemid 43053551)
7. Hjalgrim H, Askling J, Pukkala E, Hansen S, Munksgaard L, Frisch M. Incidence of Hodgkin's disease in Nordic countries. Lancet 2001; 358: 297-98. (Pubitemid 32738971)
8. Swerdlow S, Campo E, Harris N, et al. Hodgkin lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: International Agency for Research on Cancer, 2008.
9. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011; 58: 15-25.
10. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
11. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-26.
12. Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993; 71: 2062-71. (Pubitemid 23068557)
13. Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002; 119: 408-11. (Pubitemid 35365491)
14. Levis A, Pietrasanta D, Godio L, et al. A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma 2004; 5: 50-55. (Pubitemid 39136443)
15. Macintyre EA, Vaughan Hudson B, Linch DC, Vaughan Hudson G, Jelliffe AM. The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol 1987; 39: 66-70. (Pubitemid 17133243)
16. Khan A, Barrington S, Carr R. Is marrow biopsy staging for HL and DLBCL obsolete in the PET-CT era? Ann Oncol 2011; 22 (suppl 4): 43.
17. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
18. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-14.
19. Cerci JJ, Trindade E, Buccheri V, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk 2011; 11: 314-20.
20. Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91: 482-89.
21. Rigacci L, Vitolo U, Nassi L, et al, and the Intergruppo Italiano Linfomi. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007; 86: 897-903.
22. Cheson BD, Pfistner B, Juweid ME, et al, and the International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86. (Pubitemid 350002966)
23. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-94.
24. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007; 92: 771-77. (Pubitemid 350155302)
25. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52. (Pubitemid 47372616)
26. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51: 1337-43.
27. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59. (Pubitemid 43053523)
28. Hutchings M, Kostakoglu L, Zaucha J, et al. Early determination of treatment sensitivity in Hodgkin Lymphoma: FDG-PET/CT after one cycle of therapy has a higher negative predicitive value than after two cycles of chemotherapy. Ann Oncol 2011; 22 (suppl 4): 163.
29. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012; 97: 931-36.
30. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-60.
31. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502. (Pubitemid 47310889)
32. Fermé C, Eghbali H, Meerwaldt JH, et al, and the EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-27. (Pubitemid 350074687)
33. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35. (Pubitemid 46638951)
34. Press O W, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-44. (Pubitemid 33081641)
35. Specht L, Gray RG, Clarke MJ, Peto R, and the International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 1998; 16: 830-43. (Pubitemid 28108714)
36. Favier O, Heutte N, Stamatoullas-Bastard A, et al, and the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009; 115: 1680-91.
37. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835-41. (Pubitemid 41079901)
38. Eghbali H, Brice P, Creemers G-Y, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. ASH Annual Meeting Abstracts 2005; 106: 814.
39. Meyer RM, Gospodarowicz MK, Connors JM, et al, and the National Cancer Institute of Canada Clinical Trials Group, and the Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-42. (Pubitemid 46237440)
40. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA non-bulky Hodgkin disease. Blood 2004; 104: 3483-89. (Pubitemid 39564416)
41. Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 2: CD007110.
42. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366: 399-408.
43. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma version 2. http://www.nccn.org/professionals/ physician-gls/pdf/hodgkins.pdf (accessed Aug 31, 2011).
44. North London Cancer Network. North London Cancer Network (NLCN) guidelines for the management of non-Hodgkin lymphoma and Hodgkin lymphoma in adults. http://www.nlcn. nhs.uk/LeukLymphGuidelines (accessed Aug 31, 2011).
45. UK Clinical Research Nework Study Portfolio. RAPID Trial. http://public.ukcrn.org.uk/search/StudyDetail. aspx?StudyID=1299 (accessed Dec 5, 2011).
46. Andre MP, Reman O, Federico M, et al. First report on the H10 EORTC/GELA/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II Hodgkin's lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Blood 2009; 114: 97.
47. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica 2010; 95: 473.
48. Engert A, Schiller P, Josting A, et al, and the German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-08. (Pubitemid 46594052)
49. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-206.
50. Thomas J, Ferme C, Noordijk E, et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U Trial (comparing 3 chemotherapy schemes) in patients with favourable or unfavourable ealry stage Hodgkin's Lymphoma. Haematologica 2007; 92: 2 7.
51. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-13.
52. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
53. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-14. (Pubitemid 46621893)
54. Johnson PW, Radford JA, Cullen MH, et al, and the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208-18.
55. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27: 5390-96.
56. Viviani S, Zinzani PL, Rambaldi A, et al, and the Michelangelo Foundation, and the Gruppo Italiano di Terapie Innovative nei Linfomi, and the Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203-12.
57. Federico M, Luminari S, Iannitto E, et al, and the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-11.
58. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011; 29: 4227-33.
59. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998; 92: 4560-67. (Pubitemid 29005857)
60. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-54.
61. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71-76.
62. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234-42.
63. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-99.
64. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 8: CD007941.
65. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010; 21: 126-32.
66. Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010; 28: 3352-59.
67. Aleman BM, Raemaekers JM, Tirelli U, et al, and the European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-406. (Pubitemid 36682818)
68. Aleman BM, Raemaekers JM, Tomisic R, et al, and the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2007; 67: 19-30. (Pubitemid 44959502)
69. Federico M, Bellei M, Brice P, et al, and the EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 2320-25. (Pubitemid 46621870)
70. Carella AM, Bellei M, Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica 2009; 94: 146-48.
71. Proctor SJ, Mackie M, Dawson A, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795-806. (Pubitemid 34280325)
72. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-18F-FDG positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-14.
73. ClinicalTrials.gov. HD18 for advanced stages in Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00515554 (accessed Aug 31, 2011).
74. Gallamini A, Patti C, Viviani S, et al, and the Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-60.
75. Gallamini A. Multicentre clinical study with early treatment intensification in high-risk hodgkin lymphoma patients with a positive FDG-PET scan after two ABVD courses\GITL HD0607 study. Ann Oncol 2011; 22 (suppl 4): iv138-40.
76. UK Clinical Research Network Study Portfolio UCRNS. RATHL Trial. http://public.ukcrn.org.uk/search/StudyDetail. aspx?StudyID=4488 (accessed Dec 5, 2012).
77. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-54. (Pubitemid 23114397)
78. Schmitz N, Pfistner B, Sextro M, et al, and the German Hodgkin's Lymphoma Study Group, and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-71. (Pubitemid 34680969)
79. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117: 4208-17.
80. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-86. (Pubitemid 30658456)
81. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-30. (Pubitemid 34032615)
82. Cavalieri E, Matturro A, Annechini G, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 1803-08.
83. Josting A, Nogová L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 1522-29.
84. UK Clinical Research Network Study Portfolio UCRNP. PAIReD (Pilot of Allogenic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma 2011. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=6284 (accessed Aug 31, 2011).
85. Viviani S, Di Nicola M, Bonfante V, et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 2010; 51: 1251-59.
86. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010; 148: 890-97.
87. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-78. (Pubitemid 41129618)
88. Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010; 28: 5074-80.
89. Morschhauser F, Brice P, Fermé C, et al, and the GELA/SFGM Study Group. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-87.
90. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934-41. (Pubitemid 40797503)
91. Peggs KS, Sureda A, Qian W, et al, and the UK and Spanish Collaborative Groups. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139: 70-80. (Pubitemid 47389932)
92. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-62. (Pubitemid 351171699)
93. Sarina B, Castagna L, Farina L, et al, and the Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671-77.
94. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-19. (Pubitemid 30432529)
95. Oki Y, Pro B, Fayad LE, Romaguera J, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-36. (Pubitemid 351240577)
96. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
97. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010; 116: 283.
98. Younes A, Gopal AK, Smith SE, et al. Durable complete remissions in a pivotal phase 2 study of SGN-35 (brentuximab vedotin) in patients with relapsed or refractoy Hodgkin Lymphoma (HL). Ann Oncol 2011; 22 (suppl 4): iv138-40.
99. Böll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148: 480-82.
100. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-24.
101. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009; 147: 97-101.
102. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia group B protocol 50206. Leuk Lymphoma 2007; 48: 1313-19. (Pubitemid 47079358)
103. Hawkes EA, Wotherspoon A, Cunningham D. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. Leuk Lymphoma 2011; published online Sept 19. DOI:10.3109/10428194. 2011.608455.
104. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma\clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010; 21: 2061-68.
105. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793-99.
106. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631-39.
107. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110: 179-85. (Pubitemid 46986431)
108. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010; 28: 136-41.
109. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109-11.
110. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118: 4363-65.
111. Levis A, Anselmo AP, Ambrosetti A, et al, and the Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123-28. (Pubitemid 38139613)
112. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012; 119: 6005-15.
113. Pereg D, Koren G, Lishner M. The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy. Haematologica 2007; 92: 1230-37. (Pubitemid 350144182)
114. Vermoolen MA, Kwee TC, Nievelstein RA. Whole-body MRI for staging Hodgkin lymphoma in a pregnant patient. Am J Hematol 2010; 85: 443.
115. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283-91. (Pubitemid 38541580)
116. Tanaka PY, Pessoa VP Jr, Pracchia LF, Buccheri V, Chamone DA, Calore EE. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma 2007; 7: 364-68. (Pubitemid 46725239)
117. Xicoy B, Ribera J-M, Miralles P, et al, and the GESIDA Group, and the GELCAB Group. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92: 191-98.
118. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-08. (Pubitemid 34408801)
119. Cote GM, Canellos GP. Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep 2011; 6: 180-86.
120. Bhatia S, Yasui Y, Robison LL, et al, and the Late effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late effects Study Group. J Clin Oncol 2003; 21: 4386-94. (Pubitemid 46621816)
121. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25: 1489-97. (Pubitemid 46759253)
122. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29: 4096-104.
123. Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 2005; 4: CD003187.
124. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-60. (Pubitemid 44884048)
125. Baxi SS, Matasar MJ. State-of-the-art issues in Hodgkin's lymphoma survivorship. Curr Oncol Rep 2010; 12: 366-73.
126. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428-37. (Pubitemid 41520078)
127. Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009; 101: 582-88.
128. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206-14.
129. Harel S, Fermé C, Poirot C. Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica 2011; 96: 1692-99.
130. Behringer K, Breuer K, Reineke T, et al, and the German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-64. (Pubitemid 46291819)
131. Behringer K, Wildt L, Mueller H, et al, and the German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010; 21: 2052-60.
132. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601-05. (Pubitemid 15116991)
133. van der Kaaij MA, Heutte N, Le Stang N, et al, and the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group, and the Groupe d'Etude des Lymphomes de l'Adulte. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 2825-32. (Pubitemid 47134677)